Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04639089
Other study ID # MD166/2020
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 14, 2020
Est. completion date December 15, 2023

Study information

Verified date February 2022
Source Ain Shams University
Contact hamdy singab, PHD
Phone +201001008859
Email hamdi_singab@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small volume of plasma. Because it is an autogenous preparation, PRP is inherently safe and therefore free from concerns over transmissible diseases such as HIV and hepatitis. Its power of regeneration already proved by orthopedics and dentists in their trials to regenerate cartilages .We will use it to know its ability to enhance healing of sternum in vulnerable patients to sternal dehiscence after open heart surgery .


Description:

1. INTRODUCTION Successful healing of the sternum after open heart surgery is a complicated phenomenon because of the natural body ability often fails to efficiently repaired of the sternum in patients after open cardiac surgery (Everts 2006). Recent evidence based data suggested new modalities to increase the quality and accerelate sternal healing in high risk patients after open heart surgery vulnerable for early sternal dehiscence (Liu 2002) . PRP considers as an attractive alternative option in that manner. Marx and associates demonstrated the positive influence of PRP on bone regeneration and healing since 1998 (Marx 1998 ) . Autologous PRP carries minimal risk of infectious diseases transmission, immunologic reactions, and rejection. PRP with concentrations 4 to 5 folds of the normal average platelet (1,100,000 platelets/μl ) proved to have a remarkable increase in bone mineral density and regeneration . the market for PRP grows from $45 million in 2009 to more than $120 million by 2016 (Dawood 2018 ). Multiple factors affect the PRP efficacy in sternal bone healing and regeneration process. Platelet preparation before surgical application is an area of concern with PRP. For this issue, an appropriate anticoagulant must be used to prevent the early spontaneous activation of the platelets (Kassolis 2000 ). Several anticoagulants have been employed for PRP preparation including heparin, citrate, acid-citrate-dextrose solution A or anticoagulant citrate dextrose-A ,citrate-phos phate-dextrose ,citrate-theophylline-adenosine- dipyrimadole and ethylene diamine tetra- acetic acid moreover, several manual or automated systems have been designed for preparing PRP including clinical laboratory methods and kits (Carlson 2002). PRP produced by single- or double-step centrifugation technology via platelet-pheresis (autologous selective filtration )and the cell separators,However, these methods are rarely used nowadays, due to several factors including high cost, large volume of peripheral blood should be harvested from the patients, and potentially damage to the platelet (Dhurat 2014) . Commercially available PRP kits and devices differ in ease of use, one or two step centrifugation protocols, centrifugation speed, final PRP volume, platelet count and activation, platelet and growth factor concentrations, and final RBCs' and WBCs' count.Nevertheless, the cost of the commercial kits for PRP processing is still a challenge (Trebinjac 2020) . 2. AIM/ OBJECTIVES : To study the Effect of platlet rich plasma on sternal healing post median sternotomy in Patients undergoing open heart surgery 3. METHODOLOGY: - Type of Study: prospective clinical trial propensity matched comparative study - Study Setting: Patients refered to our Cardiothoracic department, Faculty of medicine, Ain Shams University and ain shams specialized hospital to perform open heart surgery who fulfill our inclusion charateria. - Study Period: It will be performed between march 2020 and january2022 - Study Population: - Inclusion Criteria: Patients with one of which 1. patients will under go open heart surgery with BMI >30 or 2. diabetic patients 3. patients with history of chest wall radiotherapy exposure or 4. bilateral internal mammary artery harvesting . 5. age > 70 years old -Exclusion Criteria: 1. patient with history of open heart surgery 2. patients with preoperative HB level <11 3. All emergency and urgency cardiothoracic surgery - Sampling Method: prospective clinical trials propensity matched comparative study. - Sample Size: 50 patients - Ethical Considerations: All the patients will sign an informed consent for operation and for being involved in the research and follow up process . - Study Tools: platlets rich plasma - Preparation technique : ultra centrifuge technique - Study Procedures: Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA Intraoperative : We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure. post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery sternal stability and absence of dehiscence will be primary out come measure Secondary end point : Severe form of sternal deheiscence After 3months: stability of sternum will be assessed By CT chest with 3D bone reconstruction and the value of bone density as aconfirmatory test - Statistical Analysis:using the arithmetic mean, standard deviation using hypothesis student's "t" tests for quantitative data analysis, while qualitative data (ordinal, categorical) will be analyzed using The chi-square test (x2) (Fisher's Exact Test). For all statistical comparisons, a P value of <0.05 will be considered significant and a P value of <0.01 will be considered highly significant. - Statistical Package:Data will be statistically analyzed using statistical package of social science (SPSS)


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 15, 2023
Est. primary completion date August 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 70 Years to 90 Years
Eligibility Inclusion Criteria: - Patients with one of which 1. patients will under go open heart surgery with BMI >30 or 2. diabetic patients 3. patients with history of chest wall radiotherapy exposure or 4. bilateral internal mammary artery harvesting . 5. age > 70 years old Exclusion Criteria: - patient with history of open heart surgery 2- patients with preoperative HB level <11 3-All emergency and urgency cardiothoracic surgery

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
platlet rich plasma on sternal healing post median sternotomy
Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA Intraoperative : We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure. post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery

Locations

Country Name City State
Egypt Hamdy Singab Cairo

Sponsors (1)

Lead Sponsor Collaborator
Dr. Hamdy Singab

Country where clinical trial is conducted

Egypt, 

References & Publications (7)

Carlson NE, Roach RB Jr. Platelet-rich plasma: clinical applications in dentistry. J Am Dent Assoc. 2002 Oct;133(10):1383-6. — View Citation

Dawood AS, Salem HA. Current clinical applications of platelet-rich plasma in various gynecological disorders: An appraisal of theory and practice. Clin Exp Reprod Med. 2018 Jun;45(2):67-74. doi: 10.5653/cerm.2018.45.2.67. Epub 2018 Jun 29. Review. — View Citation

Dhurat R, Sukesh M. Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective. J Cutan Aesthet Surg. 2014 Oct-Dec;7(4):189-97. doi: 10.4103/0974-2077.150734. Review. — View Citation

Everts PA, Knape JT, Weibrich G, Schönberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006 Jun;38(2):174-87. Review. — View Citation

Kassolis JD, Rosen PS, Reynolds MA. Alveolar ridge and sinus augmentation utilizing platelet-rich plasma in combination with freeze-dried bone allograft: case series. J Periodontol. 2000 Oct;71(10):1654-61. — View Citation

Liu Y, Kalén A, Risto O, Wahlström O. Fibroblast proliferation due to exposure to a platelet concentrate in vitro is pH dependent. Wound Repair Regen. 2002 Sep-Oct;10(5):336-40. — View Citation

Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jun;85(6):638-46. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary sternal stability and absence of dehiscence Radiographic strenal healing score information was collected from 50 patients during clinical follow-up determined by CT chest 3D axial slices analysis at five locations ( manubrium, top of aortic arch, main pulmonary artery , aortic root and aortopulmonary window) using 5 - points quantitative scale 0:minimal healing
no signs of healing
mild healing
moderate healing
complete healing
after the first 3 months of surgery
See also
  Status Clinical Trial Phase
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT01184521 - Masimo CO-Oximeter Study Phase 0
Completed NCT05537168 - Bayesian Networks in Pediatric Cardiac Surgery
Completed NCT05737147 - Comparison of the Accuracy and Precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature.
Completed NCT04269109 - Opioid Sparing Pain Management Strategy
Completed NCT04911413 - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery Phase 4
Recruiting NCT02580292 - Diagnostic Accuracy of Doppler Resistive Indices for Early Diagnosis of Acute Kidney Injury .
Completed NCT02457572 - Pulse Pressure Variation Measured During Valsalva Maneuver to Predict Fluid Responsiveness Under Open-chest Condition N/A
Completed NCT00997217 - The Effect of Remote Ischemic Preconditioning in the Cardiac Surgery Phase 1
Recruiting NCT05454735 - Glycemic Variability and Autonomic Nervous System in Cardiac Surgery Patients
Completed NCT01169441 - Lead Extract Study N/A
Completed NCT00336908 - Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery Phase 2/Phase 3
Terminated NCT05308589 - CPPF After General Cardiac Surgery N/A
Recruiting NCT03163238 - Dexmedetomidine and the Inflammatory Response in Pediatric Cardiac Surgery Phase 2
Completed NCT02329158 - Disinvestment in Hydroxyl-ethyl Starches (HES) for Cardiac Surgery
Completed NCT01029314 - Pilot Study of the Genius(TM)2 Tympanic Thermometer in Cardiac Patients Requiring Cardiopulmonary Bypass N/A
Completed NCT00459082 - A Pharmacokinetic Study of Dexmedetomine in Infants Phase 1
Completed NCT00122018 - An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery Phase 2
Terminated NCT03709693 - Clinical Outcomes in Patients Treated With SternaLock Blu
Completed NCT03976947 - Impact of Lung Recruitment Maneuvers on Driving Pressure in Cardiac Surgery